147 related articles for article (PubMed ID: 30976061)
1. Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts.
Leiting JL; Hernandez MC; Yang L; Bergquist JR; Ivanics T; Graham RP; Truty MJ
Sci Rep; 2019 Apr; 9(1):5901. PubMed ID: 30976061
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.
Butler KA; Hou X; Becker MA; Zanfagnin V; Enderica-Gonzalez S; Visscher D; Kalli KR; Tienchaianada P; Haluska P; Weroha SJ
Neoplasia; 2017 Aug; 19(8):628-636. PubMed ID: 28658648
[TBL] [Abstract][Full Text] [Related]
3. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.
Hu G; Phillips JL; Dasari S; Jacobs HK; Luchtel RA; Oishi N; Hundal T; Ahmed NH; Satou A; Epstein AL; Bennani NN; Nowakowski GS; Murray JA; Feldman AL
Leukemia; 2020 May; 34(5):1467-1471. PubMed ID: 31836854
[No Abstract] [Full Text] [Related]
4. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
[TBL] [Abstract][Full Text] [Related]
5. Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts.
Okano M; Oshi M; Butash A; Okano I; Saito K; Kawaguchi T; Nagahashi M; Kono K; Ohtake T; Takabe K
J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):27-36. PubMed ID: 32109311
[TBL] [Abstract][Full Text] [Related]
6. Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment.
Hernandez MC; Yang L; Leiting JL; Sugihara T; Bergquist JR; Ivanics T; Graham R; Truty MJ
Transl Oncol; 2019 Jan; 12(1):69-75. PubMed ID: 30273859
[TBL] [Abstract][Full Text] [Related]
7. Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma.
Jun E; Jung J; Jeong SY; Choi EK; Kim MB; Lee JS; Hong SM; Seol HS; Hwang C; Hoffman RM; Shim IK; Chang S; Kim SC
Anticancer Res; 2016 Feb; 36(2):517-21. PubMed ID: 26851005
[TBL] [Abstract][Full Text] [Related]
8. Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.
Strunz PP; Schmalzing M; Heidemeier A; Rasche L; Einsele H; Kortüm KM
Leuk Lymphoma; 2019 Dec; 60(14):3573-3576. PubMed ID: 31317812
[No Abstract] [Full Text] [Related]
9. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation.
Dieter SM; Giessler KM; Kriegsmann M; Dubash TD; Möhrmann L; Schulz ER; Siegl C; Weber S; Strakerjahn H; Oberlack A; Heger U; Gao J; Hartinger EM; Oppel F; Hoffmann CM; Ha N; Brors B; Lasitschka F; Ulrich A; Strobel O; Schmidt M; von Kalle C; Schneider M; Weichert W; Ehrenberg KR; Glimm H; Ball CR
Int J Cancer; 2017 Mar; 140(6):1356-1363. PubMed ID: 27935045
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
11. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
12. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease.
Go KL; Delitto D; Judge SM; Gerber MH; George TJ; Behrns KE; Hughes SJ; Judge AR; Trevino JG
Pancreas; 2017 Jul; 46(6):813-819. PubMed ID: 28609371
[TBL] [Abstract][Full Text] [Related]
13. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases.
Blomme A; Van Simaeys G; Doumont G; Costanza B; Bellier J; Otaka Y; Sherer F; Lovinfosse P; Boutry S; Palacios AP; De Pauw E; Hirano T; Yokobori T; Hustinx R; Bellahcène A; Delvenne P; Detry O; Goldman S; Nishiyama M; Castronovo V; Turtoi A
Oncogene; 2018 Mar; 37(9):1237-1250. PubMed ID: 29242606
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
15. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases.
Zompi S; Tulliez M; Conti F; Leblond V; Gaulard P; Blanche P; Durand F; Ghandi D; Dreyfus F; Louvel A; Calmus Y; Bouscary D
J Hepatol; 2000 Mar; 32(3):521-7. PubMed ID: 10735625
[TBL] [Abstract][Full Text] [Related]
16. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
17. Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.
Corso S; Cargnelutti M; Durando S; Menegon S; Apicella M; Migliore C; Capeloa T; Ughetto S; Isella C; Medico E; Bertotti A; Sassi F; Sarotto I; Casorzo L; Pisacane A; Mangioni M; Sottile A; Degiuli M; Fumagalli U; Sgroi G; Molfino S; De Manzoni G; Rosati R; De Simone M; Marrelli D; Saragoni L; Rausei S; Pallabazzer G; Roviello F; Cassoni P; Sapino A; Bass A; Giordano S
Neoplasia; 2018 May; 20(5):443-455. PubMed ID: 29574251
[TBL] [Abstract][Full Text] [Related]
18. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.
Guo S; Gao S; Liu R; Shen J; Shi X; Bai S; Wang H; Zheng K; Shao Z; Liang C; Peng S; Jin G
FASEB J; 2019 Jan; 33(1):873-884. PubMed ID: 30091943
[TBL] [Abstract][Full Text] [Related]
19. Cancer "Avatars": Patient-Derived Xenograft Growth Correlation with Postoperative Recurrence and Survival in Pancreaticobiliary Cancer.
Lynch IT; Abdelrahman AM; Alva-Ruiz R; Fogliati A; Graham RP; Smoot R; Truty MJ
J Am Coll Surg; 2023 Sep; 237(3):483-500. PubMed ID: 37326316
[TBL] [Abstract][Full Text] [Related]
20. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
